A Roadmap for FDA on Drug Naming
This article was originally published in RPM Report
Executive Summary
A July Institute of Medicine report on medication errors set out a multi-prong action plan for FDA and industry to improve drug naming, labeling and packaging. The report underscores that third parties are watching the agency as it develops a plan to reduce medication errors. These are the key sections from the report on drug naming.